Results 151 to 160 of about 1,575,471 (293)

Emerging drugs for partial-onset epilepsy: a review of brivaracetam

, 2016
Lan Gao,1 Shuchuen Li2 1Deakin Population Health SRC, Faculty of Health, Deakin University, Burwood, Victoria, 2School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, NSW, Australia Abstract: There are more than 12 new ...
Gao L, Li SC
core  

WITHDRAWN: Oxcarbazepine add-on for drug-resistant partial epilepsy. [PDF]

Cochrane Database Syst Rev, 2016
Castillo SM, Schmidt DB, White S, Shukralla A.   +3 more
europepmc   +1 more source

Establishing Sensory Neurons as Therapeutic Targets in Peripheral Neuropathy Driven by Polyglutamine Expanded Murine ATXN3

Annals of Neurology, EarlyView.
Repeat expansion disorders frequently involve peripheral neuropathy, yet mechanisms remain unclear. Using a spinocerebellar ataxia type 3 (SCA3) Knock‐In Atxn3Q300/Q6, we identify progressive sensorimotor deficits, peripheral nerve pathology, and dorsal root ganglia RNA splicing dysregulation.
Juan P. Mato, John M. Hayes, Jacen Emerson, Maeha Sridharan, Toluwani Adelaja, Arsal Naeem, Alexandra F. Putka, Hayley S. McLoughlin   +7 more
wiley   +1 more source

Concordance of clinical forms of epilepsy in families with several affected members

, 1993
Evidence for genetic heterogeneity in epilepsy is strong. We evaluated the concordance of clinical forms in the same family in a series of family with several cases of idiopathic epilepsy.
SPECCHIO, LUIGI MARIA, Italian League Against Epilepsy Genetic Collaborative Group   +1 more
core  

Missense variants in SLC9A6 cause partial epilepsy without neurodevelopmental delay. [PDF]

Orphanet J Rare Dis
Jiao JP, Zhang HW, Zhou XZ, Tian SJ, Gao L, Li BM, Luo JX, Wang J, Lan S, Li B, Liao WP.   +10 more
europepmc   +1 more source

Clinical Analysis of Partial Epilepsy with Auras. [PDF]

Chin Med J (Engl), 2017
Liu Y, Guo XM, Wu X, Li P, Wang WW.
europepmc   +1 more source

Accelerated Brain Atrophy in Epilepsy: A Prospective Population‐Based Study

Annals of Neurology, EarlyView.
Objective Previous longitudinal neuroimaging studies suggest that epilepsy is a progressive disorder. To date, these findings have relied largely on populations from tertiary centers, resulting in ascertainment bias, as severely affected individuals are more likely to be rescanned.
Marian Galovic, Rebecca S. N. Liu, Alex D. Everitt, Robert Terziev, Louis Lemieux, Matthias J. Koepp, John S. Duncan   +6 more
wiley   +1 more source

Lamotrigine add-on for drug-resistant partial epilepsy. [PDF]

Cochrane Database Syst Rev, 2016
Ramaratnam S, Panebianco M, Marson AG.
europepmc   +1 more source

Blood SOD1 Activity in ALS Patients Receiving Tofersen Treatment

Annals of Neurology, EarlyView.
Objective The antisense oligonucleotide tofersen is the first disease‐modifying drug for SOD1‐related amyotrophic lateral sclerosis (ALS) and was approved because of its ability to reduce SOD1 protein and neurofilament levels. The effect of tofersen on SOD1 activity is unclear but of clinical relevance because homozygous SOD1 mutations, linked to ...
Katharina Goehring, Enya Abler, Jakub Vavra, Kristina Mayer, Johannes Dorst, Zeynep Elmas, Maximilian Wiesenfarth, Lars Richter, Susanne Petri, Martin Regensburger, Peter Reilich, Bogdan Bjelica, Rea Lumi, Patrick Süß, Hayrettin Tumani, Markus Otto, Jochen H. Weishaupt, Albert C. Ludolph, Patrick Oeckl   +18 more
wiley   +1 more source